UPDATE: Stifel Nicolaus Raises Target to $57 on Nu Skin

Stifel Nicolaus remains Buy-rated on Nu Skin (NYSE: NUS) and increases its target price to $57, up $5, on the company's continued sales momentum.

Stifel Nicolaus says, "Nu Skin Enterprises reported 4Q results ahead of Street consensus resulting from stronger-than-anticipated currency neutral sales growth (up 21% y/y) driven by the 4Q introduction of ageLOC R2, the first global nutrition rollout of the company's anti-aging platform, and Galvanic Body Spa. We believe momentum is strong and sustainable as new product launches drive accelerating executive distributor growth, a strongly correlated, leading indicator of sales growth."

NUS closed at $51.82 a share on Thursday.